Study on the use of Fuyuan Tongluo capsules with intravenous thrombolysis of acute cerebral infarction
扶元通络胶囊在急性脑梗死静脉溶栓患者中的应用研究

摘要

目的 观察扶元通络胶囊在急性脑梗死静脉溶栓后患者中使用的临床疗效和安全性。方法 2021年1月2022年7月，符合纳入标准在急性期使用阿替普酶静脉溶栓的急性脑梗塞患者150例，随机分为治疗组和对照组，各75例；对照组采用内科常规疗法（稳定血管斑块、依达拉奉脑保护，24小时加用抗血小板），治疗组在对照组基础上加扶元通络胶囊（0.6g，po，tid），2组均以2周为1疗程，2周后统计疗效。结果 两组神经功能缺损程度评分（NIHSS）治疗前与治疗后有明显改善，组间比较差异有统计学意义 （P＜0.05）；两组治疗前与治疗后mRs良好例数有明显增高，组间比较差异有统计学意义 （P＜0.05）；两组治疗后HIHSS评分、mRs良好例数占比，两组比较无差异 （P>0.05）；治疗组与对照组比较，肝功肾功血常规异常例数无差异（P>0.05）；在舌象异常，疲软，纳差，口中有异味症状方面，治疗组与对照组比较，两组有差异（P＜0.05）。结论 扶元通络胶囊治疗脑梗塞急性期使用阿替普酶静脉溶栓有较好的临床疗效，无明显的药物不良损害，可改善舌象异常、疲软、纳差、口中异味等非特异性症状，值得推广。

Abstract

Objective To observe the clinical efficacy and safety of Fuyuan Tongluo capsules in patients with acute cerebral infarction after intravenous thrombolysis.
Methods From January 2021 to July 2022, 150 patients with acute cerebral infarction who met the inclusion criteria and used alteplase intravenous thrombolysis in the acute phase were randomly divided into treatment group and control group, with 75 cases each. The control group used conventional medical therapy (stabilizing vascular plaque, edaravone brain protection, 24-hour plus antiplatelets), and the treatment group added Fuyuan Tongluo capsules (0.6g, PO, TID) on the basis of the control group, and both groups were treated with 2 weeks as 1 course of treatment, and the statistical efficacy was calculated after 1 course of treatment.
Results The degree of neurological deficit score (NIHSS) was significantly improved before and after treatment between the two groups, and the difference between the groups was statistically significant (P<0.05); The number of good mRs before and after treatment increased significantly, and the difference between the groups was statistically significant (P <0.05); There was no difference between the two groups in HIHSS score and proportion of good mRs (P> 0.05). Compared with the control group, there was no difference in the number of abnormal cases of liver and kidney function and blood routine in the treatment group (P>0.05). In terms of tongue image abnormality, weakness, poor appetite, and odor symptoms in the mouth, there was a difference between the treatment group and the control group (P<0.05).
Conclusion   The use of alteplase intravenous thrombolysis in the acute stage of cerebral infarction in the treatment of cerebral infarction has good clinical efficacy, without obvious adverse drug damage, and can improve non-specific symptoms such as abnormal tongue image, weakness, poor appetite, and bad taste in the mouth, which is worth promoting.